Indefinite Delivery Contract 75N93021D00015
Award Date
10/15/20
Last Date to Order
10/14/27
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Rutgers, The State University
Ultimate Awardee
Rutgers, The State University
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC Category
AN81 - R&D- Medical: Aids Research (Basic Research)
Federal Contract Vehicle
Pricing Type
Cost No Fee
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to provide preclinical development support for candidate products addressing HIV, HBV, HCV and other infectious diseases. The multiple award ID/IQ contract holds a potential value of $107 million and a period of performance from October 2020 through October 2027. The contract establishes seven task areas for procuring services such as in vitro testing,...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. The total potential value of the IDV is $107,274,471 over seven years ending October 2027. Task orders have been issued under several areas. Lovelace Biomedical Research Institute received a $18,397 order to develop...
The National Institute of Allergy and Infectious Diseases has awarded an indefinite delivery contract with a potential value of $107,274,471 to multiple prime contractors to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Task orders will be issued under seven task areas, including in vitro testing, synthesis of therapeutic agents, small animal...
This indefinite delivery contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to support preclinical and translational vaccine development for HIV and other candidate agents. The multiple award IDV has a potential value of $364,553,934 over a seven year ordering period from December 2021 to November 2028. The contract aims to procure a broad range of capabilities for preclinical and translational development support. This includes...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. Valued at up to $107 million over seven years, the contracts authorize task orders across seven areas including in vitro testing, synthesis of therapeutic agents, small animal models, formulation development,...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple indefinite delivery/indefinite quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Services will be conducted under seven task areas including in vitro testing, synthesis of therapeutic agents, small animal models for...
The National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial discovery to clinical trials. Services are conducted under seven task areas including in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation development, preclinical pharmacology and...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, awarded an indefinite delivery/indefinite quantity (IDIQ) contract to The University of Iowa to provide preclinical development support for HIV, hepatitis B/C, and tuberculosis therapeutic candidates. The IDIQ has a ceiling value of $107,274,471 over a 7-year period of performance from October 2020 to October 2027. The contract encompasses a range of services across seven task areas,...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a single-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Lovelace Biomedical Research Institute to provide preclinical development support for candidate products and drug development activities for HIV, hepatitis, and tuberculosis. The 7-year, $107.3 million contract covers a range of services across seven task areas, including in vitro screening,...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Sri International to provide preclinical development support for candidate products and drug development activities. The $107.3M contract has a 7-year period of performance from October 2020 to October 2027. The contract encompasses a broad scope of work, including in vitro testing and screening, small...